Fig. 3From: Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitusLDL-C levels of patients according to lipid-lowering medication at baseline; all patients were on PCSK9 inhibitor therapy. Data are median (interquartile range). *Indicates statistical significance when compared to baseline LDL-C levels for all groups investigatedBack to article page